Perform® Humeral System - Fracture Study (PFX)
Study Details
Study Description
Brief Summary
This study is an international, single arm, multicenter, prospective follow-up, non-significant risk, Post-Market Clinical Follow-up (PMCF), which is designed to collect safety and performance data on commercially available Perform® Fracture.
Data collected from this study will be used for purposes, including but not limited to, PMS, peer-reviewed publications, education materials, future regulatory submissions, and/or product development.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This is an International, single arm, multicenter, prospective follow-up, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available Perform® Fracture shoulder system in both the anatomic and reversed configurations.
The primary endpoint of this study is to demonstrate decreased pain and improved subjects' shoulder functionality of daily living by achieving a mean of American Shoulder and Elbow Surgeons (ASES) shoulder score higher than 62 points, at 2-year follow-up post-operatively, regardless of configuration (anatomic or reverse).
Retrospective inclusions are allowed: preoperative and intra operative data can be collected retrospectively up to 2 months after the surgery date.
Secondary outcome measures include patient reported outcome measures (PROMs) and standard radiographic findings, including, but not limited to: bone erosion, device migration/subsidence, component breakage, radiolucency, and ossification.
Safety and performance data will be collected at surgery, immediate post-op, and up to 10 years post-operation. Patient Reported Outcome Measures (PROMs), device revision and Adverse Events (AEs) will be assessed annually throughout the study.
Range of Motion (ROM), strength and radiographic imaging assessments of the study shoulder will also be performed for in-person milestones visits at 6 months (radiographic imaging assessments), 1-, 2-, 5- and 10-year, post-operatively.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Tornier Perform® Humeral System - Fracture Commercially available convertible humeral system for anatomic and reverse shoulder arthroplasty. |
Device: Tornier Perform® Humeral System - Fracture
A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.
A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.
|
Outcome Measures
Primary Outcome Measures
- ASES Score = American Shoulder and Elbow Surgeons Score [24 Month]
11 items with total score reported out of 100 measuring pain and activity of patient's evaluated shoulder where lower scores indicate more pain and less function
Secondary Outcome Measures
- Constant Score [24 Month]
A score based on a 100-point scale determined by objective measurements made by the physician in the clinic and subjective values based on pain and activities of daily living reported by the patient. Collected at: 1, 2, 5, and 10 years.
- SANE [24 Month]
Single question that asks the patient to rate their shoulder on a scale from 0 to 100, where 100 is normal. Collected annually through 10 year visit.
- EQ-5D-5L [24 Month]
Consists of a 5-question measure where patients rate their health today on a 5-point scale on a 5-dimension scale and a visual analogue scale to measure overall health status. Collected annually through 10 year visit..
- Patient Satisfaction [24 Month]
Single subjective question "How satisfied are you with your shoulder?" Collected annually through 10 year visit.
- Radiographic Findings [24 Month]
X-rays will be analyzed, when sufficient information is available, for bone erosion, device migration/subsidence, component breakage, radiolucency, and ossification. X-rays will be collected at Baseline, 6 months, 1 year, 2 year, 5 year and 10 year.
- Tuberosity healing [12 Month]
Tuberosity healing (bone union) (Boileau et al., 2002, 2013, 2019) is expected to be completed post-operatively at 6 months and assessed at 6 months and up to 1 year if tuberosity healing is not achieved at 6 months.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years or older at the time of the informed consent or the non-opposition (when applicable)
-
Informed and willing to sign an informed consent form (ICF) approved by IRB or EC (when applicable)
-
Willing and able to comply with the requirements of the study protocol
-
Considered a candidate for shoulder arthroplasty with the device for shoulder joint disabled by:
-
Traumatic or pathologic conditions of the shoulder resulting in fracture of the glenohumeral joint, including humeral head fracture and displaced 3-or 4-part proximal humeral fractures
-
Fracture sequelae
-
Revisions where adequate fixation can be achieved, and adequate bone stock remains after final reconstruction
-
Proximal humerus bone defect (reverse configuration)
Exclusion Criteria:
-
Not able to comply with the study procedures based on the judgment of the assessor (e.g., cannot comprehend study questions, inability to keep scheduled assessment times)
-
Patient belongs to a vulnerable group of subjects, including minor subjects, those unable to decide for themselves to participate or needing a LAR, or others who could be subject to coercion (subjects who may not be acting on their own initiative) (referred as "vulnerable subject" in the section 3.44 of the ISO 14155:2011 norm)
-
Any absolute contraindications as mentioned in the device Instruction For Use (available on ifu.stryker.com)
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Stryker Trauma GmbH
Investigators
- Study Director: Arthur de Gast, MD MSc PhD, Stryker Trauma and Extremities
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UE-01-2022